First Look at EMERALD-3 Results: Dr. Rachna Shroff on Top ASCO26 Research

Dr. Rachna Shroff of the University of Arizona Cancer Center analyzes the results of the EMERALD-3 trial assessing tremelimumab plus durvalumab with or without lenvatinib combined with transarterial chemoembolization in unresectable hepatocellular carcinoma. Read the full abstract (LBA4000) from the 2026 ASCO Annual Meeting: https://www.asco.org/abstracts-presentations/259300 For more on ASCO26, visit https://dailynews.ascopubs.org/meetings/asco-annual-meeting _Data as of May 5, 2026_

Video Lainnya